Faster Please: Alnylam, Eiger & BioCryst Want Quick EMA Reviews
Executive Summary
Three companies are set to learn this week whether the European Medicines Agency will fast track its review of their soon-to-be-filed EU marketing applications.
You may also be interested in...
UK Allows Early Access To Alnylam’s Lumasiran For Ultra-Rare Disorder
UK patients diagnosed with primary hyperoxaluria Type 1 can now be prescribed lumasiran, which is still being reviewed for EU-wide approval. Patients in the US, Germany and other EU countries can also get the drug under early access schemes.
EU Accelerated Assessment Tracker
Alnylam and Eiger join the select group of companies whose products have been granted fast-track status at the European Medicines Agency
EU Review Gets Under Way For Lumasiran And Lonafarnib
The European Medicines Agency produces a monthly list of the marketing authorizations that are under review at the agency. The latest list contains just two new entries.